Moderna has two confirmed dates on the near horizon, and neither of them is the one making headlines. The company said on October 13 that it will report third-quarter 2026 results on November 6, with a conference call to follow. Before that, on October 24, comes the main event: full Phase 3 data from INTerpath-001, testing intismeran autogene in combination with Merck’s Keytruda in melanoma, to be presented at the ESMO congress during a Presidential Symposium. Moderna has scheduled an investor broadcast for the same afternoon.
Those two appointments measure entirely different things. One weighs the pipeline; the other weighs the business. Neither substitutes for the other, and neither is settled by what analysts have been doing to their price targets this week.
Two Upgrades, Two Different Messages
Oddo BHF raised its Moderna target to $251 from $170, according to media reports. No change to the investment rating was reported alongside it, so the defensible reading is a higher valuation expectation — not a fresh endorsement of the stock. Goldman Sachs moved too, lifting its target to $137 from $120 on Thursday, but kept its “Neutral” stance. Two upward revisions, in other words, that tell far from the same story.
That divergence matters more than the word “raised.” A higher target can reflect a reassessment of prospects without implying unqualified enthusiasm, and treating every hike as an equally strong vote of confidence is how investors misread the tape. There is also a currency wrinkle worth flagging: a dollar-denominated target and a euro-quoted share price are not directly comparable without conversion, so the direction of the analyst move is the meaningful signal — not a return figure derived from it.
A Sell-Off, a Rebound, and a Lot of Noise
Trading in the stock has been choppy. Reuters attributed Friday’s sell-off to profit-taking and caution following a strong rally, while the shares regained ground during Monday’s session. Media reports linked the recovery to anticipation of the study data as well as the bounce after the pullback. That is not a clean referendum on the company’s value — it is a rotating set of expectations.
Should investors sell immediately? Or is it worth buying Moderna?
The Commercial Bridge Is Being Built, Not Crossed
Beyond the price targets, one corporate announcement deserves attention because it touches the next stage of development. Tempus AI said on October 7 that it has expanded a multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene, which the two drugmakers are developing jointly. The operative word is “potential.” The partnership is concrete preparation, not confirmation that a commercial launch will succeed.
That is where the larger question sits. Valuing a therapy program eventually requires a bridge from clinical progress to economic execution. A collaboration can help build that bridge. It replaces neither trial results nor proof of commercial success.
What to Watch, and What Not to Confuse
The sequence of news demands a clean separation. The lifted target reflects one research house’s assessment. The ESMO presentation concerns clinical outcomes. The November 6 report delivers financials. Investors positioned ahead of the data release on Monday, and the stock rose — but that is anticipation, not evidence.
For anyone weighing Moderna here, the takeaway is that more optimistic price targets alone will not settle the case. The two confirmed publication dates offer distinct yardsticks against which expectations can be tested, and the October 24 readout will force the debate to be measured against presented results rather than against targets or preparatory partnerships. The appeal of the Moderna story lies in the possible connection between science and commerce. The analytical discipline lies in not treating that connection as already made.
Ad
Moderna Stock: Buy or Sell?! New Moderna Analysis from October 20 delivers the answer:
The latest Moderna figures speak for themselves: Urgent action needed for Moderna investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 20.
Moderna: Buy or sell? Read more here...
